Document Type

Article

Publication Date

10-9-2025

Comments

This article is the author’s final published version in Therapeutic Advances in Medical Oncology, Volume 17, 2025, Article number 17588359251342241.

The published version is available at https://doi.org/10.1177/17588359251342241. Copyright © The Author(s), 2025.

Abstract

What is the purpose of this PLS-P? The purpose of this plain language summary of publication is to help you understand recent findings from Part 1 of the RUBY study (full name ENGOT-EN6/GOG3031/RUBY trial). • Researchers sometimes study new combinations of already approved individual treatments to see if the combinations work well together and if they are safe to prescribe to patients. • In Part 1 of the RUBY study, the combination of dostarlimab with carboplatin-paclitaxel was investigated to see how well it worked for patients with primary advanced or recurrent endometrial cancer when compared with patients who were given placebo plus carboplatin-paclitaxel. • Patients in the RUBY study were divided into subgroups according to their biomarker status. This allowed researchers to see if biomarker status could help determine how well patients with specific biomarkers would respond to the combination of dostarlimab with carboplatin-paclitaxel. • This summary reports the results of the second data cut (the second time investigators looked at all of the data since the start of the study) of the RUBY study. At this time, researchers were looking specifically at how long patients lived and how safe the treatment was in patients who received dostarlimab with carboplatin-paclitaxel compared with those patients who received placebo plus carboplatin-paclitaxel.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

PubMed ID

41084729

Language

English

Download

Share

COinS